- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Savient Pharmaceuticals Inc. (SVNT)
by latest | most commented
-
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
-
Three Top and Bottom Market Sectors for This Week
-
Wednesday's Options Recap
-
FDA Calendar Updates: BioDelivery Sciences Worth the Wait
-
Monday's Options Recap
-
Savient Up Big on Friday
-
Friday's Options Recap
-
FDA Calendar Updates: BDSI, SVNT Deadlines Approach
-
Thursday Options Recap
-
Thursday Options Update: SVNT, WFC, EEM, MCO, XHB, EXEL, GDX, HIG
-
Saks Incorporated: Peter Schoenfeld Calls for Changes
-
FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX
-
30 Companies with Greatest Decline from Their 52 Week High
-
20 Stocks Which May Be Threatening Your Portfolio
-
20 Stocks to Avoid from Russell 2000
-
Biopharma: Instead of M&A, Think P&A
-
Wall Street Breakfast: Must-Know News
-
Biotech FDA and Clinical Trial Calendar Update
-
Friday's Options Recap
-
Updated Clinical Trial and FDA Calendars
-
SAC Capital Portfolio Update: 37 13G Filings
-
Hedge Fund Tracking: Farallon Capital Management (Thomas Steyer), Q3 2008
-
Two Near-Term Biotech Plays
-
Updated FDA Decision Calendar: Five Decisions Before Year-End
-
Backlog of Decisions Is Building at the FDA
-
Earnings Preview: Savient Pharmaceuticals
-
Tuesday Options Outlook: LEH, WM, AIG, OIH, DOX, TRA, SVNT
-
Earnings Preview: Savient Pharmaceuticals
-
Baby Boomers Retire: Health Care Spiders Surge
-
How Cramer Beat the S&P 500
-
Savient Could Cut Into Sanofi-Aventis' Uric Acid Reduction Business
-
Protalix BioTherapeutics: This Dream Could Take Time to Manifest
-
Why Cramer Is Wrong About Savient Pharmaceuticals
-
Russell 3000's Best, Worst Stocks Year to Date
-
Savient Pharmaceuticals: What Is Cramer Thinking?
-
Savient Loses Motion on Weight Gain Drug